Our results revealed that high Piezo2 expression correlated with worse outcomes of anti-CTLA4 treatment in melanoma (ICB_Vanllen2015_CTLA-4), anti-PD-1 treatment in melanoma (ICB_Gide2019 PD-1), anti-PD-L1 treatment in bladder cancer (ICB_Mariathasan2018_PD-L1) but achieved good outcomes in kidney cancer (ICB_Miao2018_ICB). The gene discussed is CTLA4; the disease is kidney cancer.